HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use EUCRISA safely and effectively. See full prescribing information for EUCRISA. EUCRISA® (crisaborole) ointment, for topical use Initial U.S. Approval: 2016 INDICATIONS AND USAGEEUCRISA is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. (1) DOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHSOintment, 2%. (3) CONTRAINDICATIONSKnown hypersensitivity to crisaborole or any component of the formulation. (4) WARNINGS AND PRECAUTIONSHypersensitivity reactions: If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy. (5.1) ADVERSE REACTIONSThe most common adverse reaction occurring in ≥1% in subjects is application site pain. (6.1)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 4/2023 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
EUCRISA Highlights (crisaborole)
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
(800)-332-1088.